Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at der var påvist tilstrækkelig effekt af at tilføje rosiglitazon til sulfonylurinstof, især glimepirid.
The Committee for Medicinal Products for Human Use (CHMP) concluded that the effectiveness of adding rosiglitazone to sulphonylureas, especially glimepiride, had been shown sufficiently.